<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with t(9;11)(p22;q23) developed in a child after intensive treatment for B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> diagnosed 12 months earlier </plain></SENT>
<SENT sid="1" pm="."><plain>His chemotherapy had consisted mainly of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, but no epipodophyllotoxins </plain></SENT>
<SENT sid="2" pm="."><plain>The combination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the cytogenetic anomaly involving bands at 11q23 and no previous exposure to epipodophyllotoxins represents a unique case of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>